Dr. Van Tine Discusses the Development of Olaratumab in Sarcoma

Toxicity of Olaratumab and DoxorubicinПодробнее

Dr. Van Tine on Collaboration and Clinical Trials in Uterine SarcomaПодробнее

Practical Implications of Using Olaratumab in Patients with STSПодробнее

Appropriate Patients for Olaratumab + DoxorubicinПодробнее

Updates in Sarcoma: 2023 West OncologyПодробнее

Early Data With Olaratumab in Soft Tissue SarcomaПодробнее

Brian Van Tine, ESMO 2019 - Pazopanib in soft tissue sarcomasПодробнее

Dr. Van Tine Discusses Potential Novel Treatment Modalities for SarcomaПодробнее

Olaratumab Plus Doxorubicin in Advanced Soft Tissue SarcomaПодробнее

Olaratumab Efficacy in Soft-Tissue SarcomaПодробнее

An Analysis of SARC021Подробнее

Dr. Van Tine on Sequencing Therapies in GISTПодробнее

Brian Van Tine, MD, on the most promising investigational agents in advanced sarcomaПодробнее

Dr. Van Tine on Arginine Deiminase for SarcomasПодробнее

Potential Novel Treatment Modalities for SarcomaПодробнее

The Role of Olaratumab in SarcomaПодробнее

Brian Van Tine, MD, considers the role of real-world outcomes in the treatment of sarcomaПодробнее

Dr. Tap on Olaratumab in Patients With Soft Tissue SarcomaПодробнее

Understanding Molecular Subtypes of SarcomaПодробнее